Compare LSTA & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSTA | GRML |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 29.2M |
| IPO Year | 2000 | 2022 |
| Metric | LSTA | GRML |
|---|---|---|
| Price | $1.54 | $3.11 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 551.1K | ★ 5.5M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.42 | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $0.99 | $0.16 |
| 52 Week High | $5.07 | $11.66 |
| Indicator | LSTA | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 50.45 |
| Support Level | $1.23 | $0.20 |
| Resistance Level | $2.11 | $11.66 |
| Average True Range (ATR) | 0.23 | 0.70 |
| MACD | 0.04 | -0.30 |
| Stochastic Oscillator | 42.61 | 3.11 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.